Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer

NARecruitingINTERVENTIONAL
Enrollment

900

Participants

Timeline

Start Date

November 5, 2020

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Prostate Cancer
Interventions
DEVICE

Decipher

The Decipher test (GenomeDx Biosciences) is a genomic test that will be performed on prostate biopsy tissue. Results will be provided to the patient and physician prior to making a treatment decision.

DEVICE

Prolaris

The Prolaris test (Myriad Genetics, Inc.) is a genomic test that will be performed on prostate biopsy tissue. Results will be provided to the patient and physician prior to making a treatment decision.

DEVICE

Oncotype Dx Genomic Prostate Score (GPS)

The Oncotype Dx GPS test (Exact Sciences corp.) is a genomic test that will be performed on prostate biopsy tissue. Results will be provided to the patient and physician prior to making a treatment decision.

OTHER

Standard of care (askMUSIC score)

AskMUSIC is a risk calculator based on standard clinical and pathologic variables (https://ask.musicurology.com/) and is generally included as part of routine clinical care.

Trial Locations (8)

10461

RECRUITING

Montefiore Medical Center, The Bronx

19104

RECRUITING

University of Pennsylvania Perelman School of Medicine, Philadelphia

27599

RECRUITING

University of North Carolina, Chapel Hill

48109

RECRUITING

University of Michigan Rogel Cancer Center, Ann Arbor

48202

RECRUITING

Henry Ford Health System, Detroit

48221

RECRUITING

Sherwood Medical Center, Detroit

49423

RECRUITING

Western Michigan Urological Associates, Holland

49503

RECRUITING

Spectrum Health Medical Group, Grand Rapids

Sponsors

Collaborators (2)

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

Myrexis Inc.

INDUSTRY

collaborator

Veracyte, Inc.

INDUSTRY

collaborator

MDx Health

INDUSTRY

lead

University of Michigan Rogel Cancer Center

OTHER

NCT04396808 - Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer | Biotech Hunter | Biotech Hunter